iiinova — where your digital self keeps evolving

Reposted by Mahdad Noursadeghi

Prof Jenny Rohn @jennyrohn.bsky.social · 22/02/2026

"Precarity is the one constant of academic science. Themes of instability thread themselves through everything we do." A brief blog post from me about the @ukri.org funding pause and who the real victims will be. occamstypewriter.org/mindthegap/2... #AcademicSky

occamstypewriter.org

In which we watch and wait | Mind the Gap

1239

Reposted by Mahdad Noursadeghi

Tom Scriba @tomscriba.bsky.social · 09/10/2025

We are inviting applications for postdoctoral fellows in immunology of TB at the South African Tuberculosis Vaccine Initiative, University of Cape Town. For more information see the attached ad: idm.uct.ac.za/media/739223

48140

Reposted by Mahdad Noursadeghi

yEFIS @yefis-immunology.bsky.social · 25/08/2025

👶✈️ Balancing caregiving and academic travel? Join Dr. Laura Pallett for "The Dual Demands of Academic Travel and Caregiving" 🗓️ Sept 25 | 🕒15:00 CEST 🔗https://tinyurl.com/yefis2025-ia2 Hosted by the Improving Academia group of yEFIS

1910

Reposted by Mahdad Noursadeghi

Gabriele Pollara @gpollara.bsky.social · 31/05/2025

In @elife.bsky.social: Type I interferon responses contribute to immune protection against mycobacterial infection doi.org/10.7554/eLif... #TBSky #IDSky #Immunosky work led by Gillian Tomlinson with support from @mnoursad.bsky.social & @innate2adaptive.bsky.social group (1/5)

doi.org

Type I interferon responses contribute to immune protection against mycobacterial infection

194

Reposted by Mahdad Noursadeghi

Tom Samuels @thomashasamuels.bsky.social · 30/04/2025

Very excited to share our new piece of work in the Lancet Global Health @lancetgh.bsky.social – Periskope-CM, a set of personalised risk prediction tools for HIV-associated cryptococcal meningitis mortality: www.thelancet.com/journals/lan... #IDsky #HIV #GlobalHealth #meningitis #fungal 1/8

thelancet.com

Lancet

132

Reposted by Mahdad Noursadeghi

Gabriele Pollara @gpollara.bsky.social · 30/04/2025

Come on down, anyone eligible for a post-doc do consider applying for this exciting project with @jennyrohn.bsky.social, @scottishwormboy.bsky.social & me! Got a touch of #UTISky #IDSky #ImmunoSky & 🧪 about it! 😉

056

Reposted by Mahdad Noursadeghi

South African Tuberculosis Vaccine Initiative (SATVI) @satviuct.bsky.social · 15/04/2025

Dr Munyaradzi Musvosvi speaks about the Titan Vaccine Research Project which will allow selection of most promising TB vaccine candidates. This work is supported by the South African mRNA Vaccine Consortium & funded by @samrcza.bsky.social @tomscriba.bsky.social www.youtube.com/watch?v=zwPM...

143

Reposted by Mahdad Noursadeghi

South African Tuberculosis Vaccine Initiative (SATVI) @satviuct.bsky.social · 15/04/2025

Immunopathology of TB: SATVI researchers discuss a groundbreaking study which investigates the role of lymph nodes in the context of mycobacterium tuberculosis infection and disease. The study was funded by a grant from @wellcomeleap.bsky.social a program of youtu.be/8_gCOAfWUpw

youtu.be

Immunopathology of TB: Studying the role of the lymph nodes in the TB spectrum.

YouTube video by SATVIUCT

022

Mahdad Noursadeghi @mnoursad.bsky.social · 11/04/2025

2 weeks to the deadline for applications to this post.. take a look, get in touch if you want hear more, don't hold back😎

035

Reposted by Mahdad Noursadeghi

Michael Marks @drmichaelmarks.bsky.social · 28/03/2025

Academic Clinical Lecturer Posts in Infection now out: for people training in ID in UK & hold/imminently completing PhD. 2 posts @lshtm.bsky.social shorturl.at/EIUIz 1 at St Georges & 1 at Kings shorturl.at/8kDY3 If interested in @lshtm.bsky.social posts get in touch. UK ID people please share!!

0612

Mahdad Noursadeghi @mnoursad.bsky.social · 27/03/2025

We’re hiring! Looking for a laboratory post-doc fellow to help us disentangle protective and pathogenic T cells in TB, so we can stratify disease-risk after infection, and develop more effective vaccines. Interdisciplinary science in the heart of London. What's not to like? More here: bit.ly/4iIEiwu

0913

Mahdad Noursadeghi @mnoursad.bsky.social · 14/12/2024

State of the art in the enigmatic and complex world of immunological determinants of TB👇

010

Reposted by Mahdad Noursadeghi

Kat Mayer-Barber,PhD @mayerbarber.bsky.social · 06/12/2024

Best #Nikolaus 🎅! Our paper on how the 🫁 microenvironment can shape #innate immunity against #viruses is out @sciimmunology.bsky.social This was a herculean effort brilliantly led by @pauljbaker.bsky.social who singlehandedly established the model in the lab during the pandemic. 🧪 #Immunosky 1/9

Graphical summary of our paper. In mice, prior lower airway exposure to diverse inflammatory stimuli, including chronic bacterial infections such as M. tuberculosis, acute bacterial infections such as pulmonary S. aureus, viral infections such as Influenza A, type-II allergic responses such as the OVA-Alum model, activation of pulmonary TLR9 by CpG or pulmonary TLR1/2 by Pam3CSK4
leads to reduced viral burden upon subsequent infection with SARS-CoV-2 (SCV2). (2) This SCV2 restriction occurs prior to induction of SCV2-specific adaptive immune responses
and is mediated through innate immune responses, including the induction of IFN-I, TNFα and IL-1 and sustained changes to the TRM (Tissue resident macrophage) cellular
compartment and the pulmonary epithelium. (3) Innate cytokine and TLR signaling to both recruited immune cells and the pulmonary epithelium creates a microenvironment in the
lung that limits early replication of SCV2. IFN-I signaling to pulmonary ECs (epithelial cells) increases expression of interferon-stimulated genes, that likely cell-intrinsically limit viral
replication. TNF- or IL-1 suppress SCV2 independently of IFN-I signaling. TNF acts exclusively through radio-resistant cell types such as the lung epithelium, whereas IL-1 affords
control both direct and indirectly, through either stromal and hematopoietic cell types, to restrict overall early SCV2 burden.

2829584

Reposted by Mahdad Noursadeghi

Gabriele Pollara @gpollara.bsky.social · 01/12/2024

Cool illustration how informative human challenge models can be! Here #SARSCoV2 challenge model has identified: 👉 insights into differential regulation of IFN-stimulated genes 👉 potential diagnostic biomarkers for early (MX1) & late (IFI27) viral infections #IDSky #ImmunoSky #COVID19 #MedSky 🧪

3256

Mahdad Noursadeghi @mnoursad.bsky.social · 30/11/2024

Reposting for anyone who hasn't clocked this paper yet- fab analysis by @gushamilton.bsky.social @gpollara.bsky.social and team - persuaded anti-IL6 unlikely to increase TB risk , and now need to test it's potential as therapeutic to reduce immunopath. What else can we infer about TB immunology?

252

Mahdad Noursadeghi @mnoursad.bsky.social · 26/11/2024

exciting.. congratulations @gpollara.bsky.social @jennyrohn.bsky.social - look forward to hearing more about it

110